Current Research Studies

SC-2044: A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants with Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)

SC-2044

  • Condition(s): Leukemia, other, Lymphoid Leukemia
  • Phase: I/II
  • Clinicaltrials.gov ID: NCT07134088

What is the goal of the study?

This is a multicenter, non-randomized, phase 1b/2 study in pediatric participants ≥ 28 days to < 12 years of age, at the time of enrollment, with R/R and MRD+ B-ALL, evaluating the safety, tolerability, pharmacokinetics (PK) and efficacy of subcutaneous (SC) blinatumomab.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: